Understanding the genetic structure of ASXL1-mutated myelofibrosis
Clonal Architecture of ASXL1-mutated Myelofibrosis
This study is trying to understand how ASXL1 mutations affect the survival and risk of leukemia in people with myelofibrosis by looking at blood samples from 50 patients over four years.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Angers Government |
| Locations | 13 sites (Angers and 12 other locations) |
| Trial ID | NCT05710211 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the clonal architecture of patients with ASXL1 mutations in primary and secondary myelofibrosis to better understand its prognostic implications. It will involve a multicenter cohort of 50 patients, with blood samples collected within 18 months of diagnosis. Over a follow-up period of four years, data on patient survival and potential leukemic transformation will be gathered to refine the prognostic impact of ASXL1 mutations.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with ASXL1-mutated primary or secondary myelofibrosis.
Not a fit: Patients with another active hematological disease or cancer at the time of diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic assessments and treatment strategies for patients with ASXL1-mutated myelofibrosis.
How similar studies have performed: While the clonal architecture of myelofibrosis is not extensively studied, similar approaches in other hematological conditions have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (age ≥18 years), * Affiliated to the national social security system, * ASXL1 mutated primary or secondary myelofibrosis, * Signed the consent to participate in the study, * Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM). Exclusion Criteria: * Patient with another active hematological disease or cancer at the time of diagnosis, * Person subject to legal protection scheme or incapable of giving consent.
Where this trial is running
Angers and 12 other locations
- CHU Angers — Angers, France (Recruiting)
- CHRU Brest — Brest, France (Not_yet_recruiting)
- CH Cholet — Cholet, France (Not_yet_recruiting)
- CHU Henri MONDOR — Créteil, France (Recruiting)
- Institut Paoli Calmettes — Marseille, France (Recruiting)
- CHU Nantes — Nantes, France (Not_yet_recruiting)
- AP-HP Hôpital Saint Louis — Paris, France (Not_yet_recruiting)
- Hôpital Bicêtre — Paris, France (Recruiting)
- CHU de Bordeaux — Pessac, France (Recruiting)
- CHU Lyon — Pierre-Bénite, France (Recruiting)
- CH de Cornouaille — Quimper, France (Not_yet_recruiting)
- CHRU Tours - Hôpital Bretonneau — Tours, France (Recruiting)
- CH de Vannes — Vannes, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Margaux Wiber, PharmD.
- Email: margaux.wiber@chu-angers.fr
- Phone: 0033241355553
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.